InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,528.00
(
0.90%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
68,863.71
(
-0.64%
)
Post# of 8163
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Penny Roger$

Send PM Follow Ignore
Followers 1106
Posts 279775
Boards Moderated 10
Alias Born 03/18/2011

Penny Roger$

Re: None

Thursday, 01/14/2016 3:41:25 PM

Thursday, January 14, 2016 3:41:25 PM

Post# of 8163

$IMNP ~ Bertilimumab was originally developed by Cambridge Antibody Technology (now part of MedImmune, the biologics division of AstraZeneca). CAT licensed Bertilimumab to iCo Therapeutics, who retains the rights to develop ophthalmic indications (Kerato-conjunctivitis, wet Age-related Macular Degeneration) while Immune Pharmaceuticals took responsibility for product supply and all non-ophthalmic indications in June 2011.

http://www.immunepharma.com/product-portfolio/bertilimumab-draft/

$IMNP Website: http://www.immunepharmaceuticals.com/
$IMNP News: http://finance.yahoo.com/q/h?s=IMNP+Headlines
$IMNP Live Chart: http://stockcharts.com/c-sc/sc?s=IMNP&p=d&b=7&g=0&i=p87425001600

Do your DD! Spend only the money you can afford to lose, while still willing to play at other tables. Commissions are cheaper than losses!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up